Accordingly, caution will be needed in the pursuit of therapeutic approaches that target TLR4 activation by its endogenous ligands, and much remains still to be learned regarding the optimal dosing and timing of such interventions in SSc. Here, TLR4 is linked to systemic sclerosis.